Clinical Trials Logo

Clinical Trial Summary

In this study, an APA program by web (e-APA) will be offered to two groups of participants (21 patients and 21 healthy volunteers (HV)) in remote video (use of the SAPATIC (Santé Activités Physiques Adaptées utilisant les Technologies de l'Information et de la Communication) platform developed by the company V@SI). At the same time, two control groups, a group of 21 patients and a group of 21 HV will undergo an health education program (HE) through the collaborative SAPATIC health platform of V@Si and will constitute the control groups. The content of the APA sessions will be administered by V@Si. This program offers content aimed to improve aerobic capacity and muscular strength while relying on the motivation of the participants


Clinical Trial Description

The main objective is to demonstrate that APA can improve cerebral plasticity in patients with schizophrenic or schizoaffective disorders (SCZ), reflected by an increase in the overall volume of hippocampus.

The secondary objectives will also be to assess the impact of APA on the SCZ compared to the HV:

1. on other cerebral variables (changes in the different subregions of the hippocampus (Cornu Ammonis (CA: CA1,CA2-3-4), subiculum and dentate gyrus), cortical thickness, N-acetyl aspartate (NAA) and glutamate as well as changes in the white matter through the diffusion markers (fractional anisotropy, radial diffusivity and mean diffusivity in the frontomedial-hippocampal fibers) and cerebral irrigation

2. on physiological variables (neuromuscular, cardiovascular (heart rate variability) and aerobic)

3. on cognitive variables by measuring working memory, episodic memory, attentional and executive functions

4. on circadian rhythms (temperature, actimetry and wake-sleep cycle)

5. on the clinical status of patients (severity of symptoms, quality of life, level of activity and physical abilities).

6. on biological variables (fasting glucose, triglycerides, total cholesterol, High-density lipoprotein cholesterol (HDLc), Low-density lipoprotein cholesterol (LDLc) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03261817
Study type Interventional
Source University Hospital, Caen
Contact Sonia Dollfus, Prof
Phone +33231065018
Email dollfus-s@chu-caen.fr
Status Recruiting
Phase N/A
Start date September 29, 2017
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Active, not recruiting NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Recruiting NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A
Completed NCT02304432 - Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine Early Phase 1
Completed NCT01222793 - Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia N/A
Enrolling by invitation NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Recruiting NCT02868879 - Anatomical and Structural Connectivity in Two Psychotic Phenotypes : Periodic Catatonia and Cataphasia
Completed NCT02212041 - Electronic Cigarettes in Smokers With Mental Illness N/A
Suspended NCT01878513 - Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis N/A
Recruiting NCT03163706 - Evaluation of Stroop Effect in Patients With Schizophrenia N/A
Enrolling by invitation NCT00001921 - Electrophysiology and Blood Flow in Patients With Schizophrenia and Their Siblings
Not yet recruiting NCT02879604 - Cost-utility Study of a Group of Compensatory Cognitive Remediation in Schizophrenia N/A
Recruiting NCT02906553 - The Role of Nitric Oxide in Cognition in Schizophrenia N/A
Recruiting NCT02796144 - MEtformin and Lorcaserin for WeighT Loss in Schizophrenia Phase 4
Recruiting NCT02832401 - The Impact of Caffeine on Cognition in Schizophrenia N/A
Recruiting NCT02864576 - Cognitive Remediation Plus Aerobic Exercise in Schizophrenia Treatment N/A
Recruiting NCT02874573 - Tocilizumab in Schizophrenia Phase 1
Recruiting NCT02782442 - "Cognitive Training Delivered Remotely to Individuals With Psychosis N/A